KR20190124300A - 자폐 스펙트럼 장애의 치료를 위한 방법 - Google Patents

자폐 스펙트럼 장애의 치료를 위한 방법 Download PDF

Info

Publication number
KR20190124300A
KR20190124300A KR1020197029841A KR20197029841A KR20190124300A KR 20190124300 A KR20190124300 A KR 20190124300A KR 1020197029841 A KR1020197029841 A KR 1020197029841A KR 20197029841 A KR20197029841 A KR 20197029841A KR 20190124300 A KR20190124300 A KR 20190124300A
Authority
KR
South Korea
Prior art keywords
cord blood
months
umbilical cord
patient
behavioral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197029841A
Other languages
English (en)
Korean (ko)
Inventor
조앤 커츠버그
제럴딘 도슨
제시 트로이
제시카 선
Original Assignee
듀크 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀크 유니버시티 filed Critical 듀크 유니버시티
Publication of KR20190124300A publication Critical patent/KR20190124300A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/163—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state by tracking eye movement, gaze, or pupil change
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Radiology & Medical Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
KR1020197029841A 2017-03-13 2018-03-13 자폐 스펙트럼 장애의 치료를 위한 방법 Ceased KR20190124300A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470431P 2017-03-13 2017-03-13
US62/470,431 2017-03-13
PCT/US2018/022174 WO2018169952A1 (en) 2017-03-13 2018-03-13 Methods for the treatment of autism spectrum disorders

Publications (1)

Publication Number Publication Date
KR20190124300A true KR20190124300A (ko) 2019-11-04

Family

ID=63522569

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197029841A Ceased KR20190124300A (ko) 2017-03-13 2018-03-13 자폐 스펙트럼 장애의 치료를 위한 방법

Country Status (4)

Country Link
US (2) US10912801B2 (https=)
JP (1) JP2020510049A (https=)
KR (1) KR20190124300A (https=)
WO (1) WO2018169952A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112113921B (zh) * 2020-08-12 2021-11-26 华南农业大学 一种用于待测样品间麦角硫因含量高低的高通量检测方法及其应用
WO2025064634A1 (en) * 2023-09-20 2025-03-27 Rutgers, The State University Of New Jersey Techniques for measuring or modifying control in digital interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160724B2 (en) 2000-03-09 2007-01-09 University Of South Florida Human cord blood as a source of neural tissue for repair of the brain and spinal cord
EP1664336A2 (en) 2003-09-11 2006-06-07 University College Cork-National University of Ireland, Cork A detection method for autism and related disorders
HK1205767A1 (en) * 2012-07-26 2015-12-24 The Regents Of The University Of California Screening, diagnosis and prognosis of autism and other developmental disorders
KR20140066550A (ko) * 2012-11-23 2014-06-02 의료법인 성광의료재단 제대혈 유래 줄기세포와 에리트로포이에틴을 포함하는 유전자 질환을 포함하는 발달장애 치료용 약학적 조성물

Also Published As

Publication number Publication date
US10912801B2 (en) 2021-02-09
US20210244772A1 (en) 2021-08-12
WO2018169952A1 (en) 2018-09-20
JP2020510049A (ja) 2020-04-02
US11813294B2 (en) 2023-11-14
US20200069741A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
Dawson et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial
Dawson et al. A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder
Guastella et al. Oxytocin treatment, circuitry, and autism: a critical review of the literature placing oxytocin into the autism context
Munesue et al. Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study
Rueve et al. Violence and mental illness
Sharma et al. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study
Meilleur et al. Regression of language and non‐language skills in pervasive developmental disorders
Xiong et al. Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD)
Raja et al. Asperger’s disorder in the emergency psychiatric setting
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
EP3773486B1 (en) Umbilical cord tissue-derived mesenchymal stromal cells for use in the treatment of autism spectrum disorders
Whitney et al. The epilepsy phenotype of ST3GAL3‐related developmental and epileptic encephalopathy
Keller et al. Clinical pearls to manage cyberchondriacs
Menolascino et al. Diagnosis and management of depression and suicidal behavior in persons with severe mental retardation
Azuar et al. Behavioral disorders: the ‘blind spot’of neurology and psychiatry
Fuh et al. Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population
Alkhatib et al. Behavioral Interventions with and without Pharmacological Treatment: A Comparative Study at An Autistic Center in Jordan.
Vannucchi Depressive and bipolar disorders in persons with intellectual disability and low-functioning autism spectrum disorder. The development and first validation of a new diagnostic tool (SPADD-M)
Ratheesh et al. Special considerations in the psychiatric evaluation across the lifespan (special emphasis on children, adolescents, and elderly)
Kay Attachment and its disorders
Matson et al. Comorbidity and the need for interdisciplinary treatments
McErlean et al. Perinatal Anxiety and Depression: associations with oxytocin and mother-infant interactions
Fatheddine et al. Ekbom Syndrome: A Case Study
Rong Adult outcomes of pediatric-onset CHD2 and SYNGAP1-associated developmental and epileptic encephalopathies
Taylor et al. Problematic behavior in children with epilepsy: issues and management

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210309

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220721

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230626

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220721

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I